시장조사 보고서 : 세계의 리포좀 및 지질 나노 입자 약품 시장예측 2021년-2026년

■ 영문 제목 : Global Liposomal and Lipid-based Nanoparticle Drug Market Growth (Status and Outlook) 2021-2026
	■ 상품코드 : LPI-2201K00089 ■ 조사/발행회사 : LP Information ■ 발행일 : 2021년 12월 (※2025년 최신판이 있습니다. 문의 주세요.) ■ 페이지수 : 126 ■ 작성언어 : 영어 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 ■ 조사대상 지역 : 글로벌 ■ 산업 분야 : 의료, 제약

■ 판매가격 / 옵션 (부가세 10% 별도)

Single User (1명 열람용)	USD3,660 ⇒환산￦4,941,000	견적의뢰/주문/질문
Multi User (5명 열람용)	USD5,490 ⇒환산￦7,411,500	견적의뢰/주문/질문
Corporate User (동일기업내 공유가능)	USD7,320 ⇒환산￦9,882,000	견적의뢰/구입/질문

※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.

본 조사보고서는 리포좀 및 지질 나노 입자 약품의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국, 이탈리아, 러시아, 중동/아프리카, 이집트, 남아프리카, 터키, 중동GCC국 등), 시장동향, 판매/유통업자/고객 리스트, 시장예측 (2021년-2026년), 주요 기업동향 (기업정보, 제품, 판매량, 매출, 가격, 매출총이익) 등의 정보를 포함하고 있습니다. 또한, 주요지역의 종류별 시장규모 (리포좀약, 지질 나노입자약)와 용도별 시장규모 (병원, 소매 약국, 기타) 데이터도 수록되어 있습니다.
- 조사 범위
- 경영자용 요약
- 기업별 리포좀 및 지질 나노 입자 약품 시장 점유율
- 지역별 리포좀 및 지질 나노 입자 약품 시장규모
- 주요지역의 종류별 시장규모 (리포좀약, 지질 나노입자약)
- 주요지역의 용도별 시장규모 (병원, 소매 약국, 기타)
- 미주의 리포좀 및 지질 나노 입자 약품 시장규모 (미국, 캐나다, 멕시코, 브라질 등)
- 아시아의 리포좀 및 지질 나노 입자 약품 시장규모 (중국, 일본, 한국, 동남아시아, 인도 등)
- 유럽의 리포좀 및 지질 나노 입자 약품 시장규모 (독일, 프랑스, 영국, 이탈리아, 러시아 등)
- 중동/아프리카의 리포좀 및 지질 나노 입자 약품 시장규모 (이집트, 남아프리카, 터키, 중동GCC지역 등)
- 시장의 성장요인, 과제, 동향
- 마케팅, 유통업자, 고객리스트
- 세계의 리포좀 및 지질 나노 입자 약품 시장예측 (2021년-2026년)
- 주요 기업동향 (기업정보, 제품, 판매량, 매출, 가격, 매출총이익)
Johnson & Johnson, Sun Pharmaceutical, CSPC, Kinyond, Teva, Fudan-Zhangjiang, Zydus Cadila, TTY Biopharma, Pacira, Luye Pharma, Leadiant Biosciences, Ipsen, Sayre Therapeutics, Jazz, Alnylam, Bausch Health, Acrotech Biopharma, Takeda, Chiesi Farmaceutici, Gilead Sciences
- 조사의 결과/결론

■ 보고서 개요

According to this latest study, the 2021 growth of Liposomal and Lipid-based Nanoparticle Drug will have significant change from previous year. By the most conservative estimates of global Liposomal and Lipid-based Nanoparticle Drug market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ xx million in 2020. Over the next five years the Liposomal and Lipid-based Nanoparticle Drug market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2026.

This report presents a comprehensive overview, market shares, and growth opportunities of Liposomal and Lipid-based Nanoparticle Drug market by product type, application, key players and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021 in Section 2.3; and forecast to 2026 in section 10.7.
Liposomes Drugs
Lipid Nanoparticle Drugs

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 10.8.
Hospital
Retail Pharmacy
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
Pacira
Luye Pharma
Leadiant Biosciences
Ipsen
Sayre Therapeutics
Jazz
Alnylam
Bausch Health
Acrotech Biopharma
Takeda
Chiesi Farmaceutici
Gilead Sciences

■ 보고서 목차

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Size 2016-2026
2.1.2 Liposomal and Lipid-based Nanoparticle Drug Market Size CAGR by Region 2020 VS 2021 VS 2026
2.2 Liposomal and Lipid-based Nanoparticle Drug Segment by Type
2.2.1 Liposomes Drugs
2.2.2 Liposomes Drugs
2.3 Liposomal and Lipid-based Nanoparticle Drug Market Size by Type
2.3.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Size CAGR by Type
2.3.2 Global Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Type (2016-2021)
2.4 Liposomal and Lipid-based Nanoparticle Drug Segment by Application
2.4.1 Hospital
2.4.2 Retail Pharmacy
2.4.3 Other
2.5 Liposomal and Lipid-based Nanoparticle Drug Market Size by Application
2.5.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Size CAGR by Application
2.5.2 Global Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Application (2016-2021)

3 Liposomal and Lipid-based Nanoparticle Drug Market Size by Players
3.1 Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Players
3.1.1 Global Liposomal and Lipid-based Nanoparticle Drug Revenue by Players (2019-2021E)
3.1.2 Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Players (2019-2021E)
3.2 Global Liposomal and Lipid-based Nanoparticle Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2019-2021E)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 Liposomal and Lipid-based Nanoparticle Drug by Regions
4.1 Liposomal and Lipid-based Nanoparticle Drug Market Size by Regions (2016-2021)
4.2 Americas Liposomal and Lipid-based Nanoparticle Drug Market Size Growth (2016-2021)
4.3 APAC Liposomal and Lipid-based Nanoparticle Drug Market Size Growth (2016-2021)
4.4 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Growth (2016-2021)
4.5 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Growth (2016-2021)

5 Americas
5.1 Americas Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2016-2021)
5.2 Americas Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2021)
5.3 Americas Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2021)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC
6.1 APAC Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2016-2021)
6.2 APAC Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2021)
6.3 APAC Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2021)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 Europe
7.1 Europe Liposomal and Lipid-based Nanoparticle Drug by Country (2016-2021)
7.2 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2021)
7.3 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2021)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 Middle East & Africa
8.1 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug by Region (2016-2021)
8.2 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2021)
8.3 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2021)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Global Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.1 Global Liposomal and Lipid-based Nanoparticle Drug Forecast by Regions (2021-2026)
10.1.1 Global Liposomal and Lipid-based Nanoparticle Drug Forecast by Regions (2021-2026)
10.1.2 Americas Liposomal and Lipid-based Nanoparticle Drug Forecast
10.1.3 APAC Liposomal and Lipid-based Nanoparticle Drug Forecast
10.1.4 Europe Liposomal and Lipid-based Nanoparticle Drug Forecast
10.1.5 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Forecast
10.2 Americas Liposomal and Lipid-based Nanoparticle Drug Forecast by Countries (2021-2026)
10.2.1 United States Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.2.2 Canada Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.2.3 Mexico Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.2.4 Brazil Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.3 APAC Liposomal and Lipid-based Nanoparticle Drug Forecast by Region (2021-2026)
10.3.1 China Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.3.2 Japan Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.3.3 Korea Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.3.4 Southeast Asia Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.3.5 India Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.3.6 Australia Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.4 Europe Liposomal and Lipid-based Nanoparticle Drug Forecast by Country (2021-2026)
10.4.1 Germany Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.4.2 France Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.4.3 UK Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.4.4 Italy Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.4.5 Russia Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.5 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Forecast by Region (2021-2026)
10.5.1 Egypt Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.5.2 South Africa Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.5.3 Israel Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.5.4 Turkey Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.5.5 GCC Countries Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.6 Global Liposomal and Lipid-based Nanoparticle Drug Forecast by Type (2021-2026)
10.7 Global Liposomal and Lipid-based Nanoparticle Drug Forecast by Application (2021-2026)

11 Key Players Analysis
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Information
11.1.2 Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.1.3 Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2019-2021)
11.1.4 Johnson & Johnson Main Business Overview
11.1.5 Johnson & Johnson Latest Developments
11.2 Sun Pharmaceutical
11.2.1 Sun Pharmaceutical Company Information
11.2.2 Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.2.3 Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2019-2021)
11.2.4 Sun Pharmaceutical Main Business Overview
11.2.5 Sun Pharmaceutical Latest Developments
11.3 CSPC
11.3.1 CSPC Company Information
11.3.2 CSPC Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.3.3 CSPC Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2019-2021)
11.3.4 CSPC Main Business Overview
11.3.5 CSPC Latest Developments
11.4 Kinyond
11.4.1 Kinyond Company Information
11.4.2 Kinyond Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.4.3 Kinyond Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2019-2021)
11.4.4 Kinyond Main Business Overview
11.4.5 Kinyond Latest Developments
11.5 Teva
11.5.1 Teva Company Information
11.5.2 Teva Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.5.3 Teva Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2019-2021)
11.5.4 Teva Main Business Overview
11.5.5 Teva Latest Developments
11.6 Fudan-Zhangjiang
11.6.1 Fudan-Zhangjiang Company Information
11.6.2 Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.6.3 Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2019-2021)
11.6.4 Fudan-Zhangjiang Main Business Overview
11.6.5 Fudan-Zhangjiang Latest Developments
11.7 Zydus Cadila
11.7.1 Zydus Cadila Company Information
11.7.2 Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.7.3 Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2019-2021)
11.7.4 Zydus Cadila Main Business Overview
11.7.5 Zydus Cadila Latest Developments
11.8 TTY Biopharma
11.8.1 TTY Biopharma Company Information
11.8.2 TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.8.3 TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2019-2021)
11.8.4 TTY Biopharma Main Business Overview
11.8.5 TTY Biopharma Latest Developments
11.9 Pacira
11.9.1 Pacira Company Information
11.9.2 Pacira Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.9.3 Pacira Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2019-2021)
11.9.4 Pacira Main Business Overview
11.9.5 Pacira Latest Developments
11.10 Luye Pharma
11.10.1 Luye Pharma Company Information
11.10.2 Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.10.3 Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2019-2021)
11.10.4 Luye Pharma Main Business Overview
11.10.5 Luye Pharma Latest Developments
11. Leadiant Biosciences
11.11.1 Leadiant Biosciences Company Information
11.11.2 Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.11.3 Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2019-2021)
11.11.4 Leadiant Biosciences Main Business Overview
11.11.5 Leadiant Biosciences Latest Developments
11.12 Ipsen
11.12.1 Ipsen Company Information
11.12.2 Ipsen Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.12.3 Ipsen Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2019-2021)
11.12.4 Ipsen Main Business Overview
11.12.5 Ipsen Latest Developments
11.13 Sayre Therapeutics
11.13.1 Sayre Therapeutics Company Information
11.13.2 Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.13.3 Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2019-2021)
11.13.4 Sayre Therapeutics Main Business Overview
11.13.5 Sayre Therapeutics Latest Developments
11.14 Jazz
11.14.1 Jazz Company Information
11.14.2 Jazz Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.14.3 Jazz Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2019-2021)
11.14.4 Jazz Main Business Overview
11.14.5 Jazz Latest Developments
11.15 Alnylam
11.15.1 Alnylam Company Information
11.15.2 Alnylam Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.15.3 Alnylam Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2019-2021)
11.15.4 Alnylam Main Business Overview
11.15.5 Alnylam Latest Developments
11.16 Bausch Health
11.16.1 Bausch Health Company Information
11.16.2 Bausch Health Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.16.3 Bausch Health Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2019-2021)
11.16.4 Bausch Health Main Business Overview
11.16.5 Bausch Health Latest Developments
11.17 Acrotech Biopharma
11.17.1 Acrotech Biopharma Company Information
11.17.2 Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.17.3 Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2019-2021)
11.17.4 Acrotech Biopharma Main Business Overview
11.17.5 Acrotech Biopharma Latest Developments
11.18 Takeda
11.18.1 Takeda Company Information
11.18.2 Takeda Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.18.3 Takeda Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2019-2021)
11.18.4 Takeda Main Business Overview
11.18.5 Takeda Latest Developments
11.19 Chiesi Farmaceutici
11.19.1 Chiesi Farmaceutici Company Information
11.19.2 Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.19.3 Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2019-2021)
11.19.4 Chiesi Farmaceutici Main Business Overview
11.19.5 Chiesi Farmaceutici Latest Developments
11.20 Gilead Sciences
11.20.1 Gilead Sciences Company Information
11.20.2 Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.20.3 Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2019-2021)
11.20.4 Gilead Sciences Main Business Overview
11.20.5 Gilead Sciences Latest Developments

12 Research Findings and Conclusion

List of Tables
Table 1. Liposomal and Lipid-based Nanoparticle Drug Market Size CAGR by Region (2020-2026) & ($ Millions)
Table 2. Major Players of Liposomes Drugs
Table 3. Major Players of Lipid Nanoparticle Drugs
Table 4. Liposomal and Lipid-based Nanoparticle Drug Market Size CAGR by Type (2020-2026) & ($ Millions)
Table 5. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2021) & ($ Millions)
Table 6. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Type (2016-2021)
Table 7. Liposomal and Lipid-based Nanoparticle Drug Market Size CAGR by Application (2016-2021) & ($ Millions)
Table 8. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2021) & ($ Millions)
Table 9. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Application (2016-2021)
Table 10. Global Liposomal and Lipid-based Nanoparticle Drug Revenue by Players (2019-2021E) & ($ Millions)
Table 11. Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Players (2019-2021E)
Table 12. Liposomal and Lipid-based Nanoparticle Drug Key Players Head office and Products Offered
Table 13. Liposomal and Lipid-based Nanoparticle Drug Concentration Ratio (CR3, CR5 and CR10) & (2019-2021E)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Regions 2016-2021 & ($ Millions)
Table 17. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Regions 2016-2021
Table 18. Americas Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2016-2021) & ($ Millions)
Table 19. Americas Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Country (2016-2021)
Table 20. Americas Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2021) & ($ Millions)
Table 21. Americas Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Type (2016-2021)
Table 22. Americas Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2021) & ($ Millions)
Table 23. Americas Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Application (2016-2021)
Table 24. APAC Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2016-2021) & ($ Millions)
Table 25. APAC Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Region (2016-2021)
Table 26. APAC Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2021) & ($ Millions)
Table 27. APAC Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Type (2016-2021)
Table 28. APAC Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2021) & ($ Millions)
Table 29. APAC Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Application (2016-2021)
Table 30. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2016-2021) & ($ Millions)
Table 31. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Country (2016-2021)
Table 32. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2021) & ($ Millions)
Table 33. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Type (2016-2021)
Table 34. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2021) & ($ Millions)
Table 35. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Application (2016-2021)
Table 36. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2016-2021) & ($ Millions)
Table 37. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Region (2016-2021)
Table 38. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2016-2021) & ($ Millions)
Table 39. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Type (2016-2021)
Table 40. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2016-2021) & ($ Millions)
Table 41. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Application (2016-2021)
Table 42. Key and Potential Regions of Liposomal and Lipid-based Nanoparticle Drug
Table 43. Key Application and Potential Industries of Liposomal and Lipid-based Nanoparticle Drug
Table 44. Key Challenges of Liposomal and Lipid-based Nanoparticle Drug
Table 45. Key Trends of Liposomal and Lipid-based Nanoparticle Drug
Table 46. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Forecast by Regions (2021-2026) & ($ Millions)
Table 47. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share Forecast by Regions (2021-2026)
Table 48. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Forecast by Type (2021-2026) & ($ Millions)
Table 49. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share Forecast by Type (2021-2026)
Table 50. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Forecast by Application (2021-2026) & ($ Millions)
Table 51. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share Forecast by Application (2021-2026)
Table 52. Johnson & Johnson Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 53. Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 54. Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 55. Johnson & Johnson Main Business
Table 56. Johnson & Johnson Latest Developments
Table 57. Sun Pharmaceutical Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 58. Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 59. Sun Pharmaceutical Main Business
Table 60. Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 61. Sun Pharmaceutical Latest Developments
Table 62. CSPC Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 63. CSPC Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 64. CSPC Main Business
Table 65. CSPC Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 66. CSPC Latest Developments
Table 67. Kinyond Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 68. Kinyond Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 69. Kinyond Main Business
Table 70. Kinyond Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 71. Kinyond Latest Developments
Table 72. Teva Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 73. Teva Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 74. Teva Main Business
Table 75. Teva Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 76. Teva Latest Developments
Table 77. Fudan-Zhangjiang Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 78. Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 79. Fudan-Zhangjiang Main Business
Table 80. Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 81. Fudan-Zhangjiang Latest Developments
Table 82. Zydus Cadila Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 83. Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 84. Zydus Cadila Main Business
Table 85. Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 86. Zydus Cadila Latest Developments
Table 87. TTY Biopharma Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 88. TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 89. TTY Biopharma Main Business
Table 90. TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 91. TTY Biopharma Latest Developments
Table 92. Pacira Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 93. Pacira Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 94. Pacira Main Business
Table 95. Pacira Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 96. Pacira Latest Developments
Table 97. Luye Pharma Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 98. Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 99. Luye Pharma Main Business
Table 100. Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 101. Luye Pharma Latest Developments
Table 102. Leadiant Biosciences Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 103. Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 104. Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 105. Leadiant Biosciences Main Business
Table 106. Leadiant Biosciences Latest Developments
Table 107. Ipsen Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 108. Ipsen Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 109. Ipsen Main Business
Table 110. Ipsen Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 111. Ipsen Latest Developments
Table 112. Sayre Therapeutics Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 113. Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 114. Sayre Therapeutics Main Business
Table 115. Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 116. Sayre Therapeutics Latest Developments
Table 117. Jazz Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 118. Jazz Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 119. Jazz Main Business
Table 120. Jazz Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 121. Jazz Latest Developments
Table 122. Alnylam Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 123. Alnylam Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 124. Alnylam Main Business
Table 125. Alnylam Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 126. Alnylam Latest Developments
Table 127. Bausch Health Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 128. Bausch Health Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 129. Bausch Health Main Business
Table 130. Bausch Health Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 131. Bausch Health Latest Developments
Table 132. Acrotech Biopharma Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 133. Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 134. Acrotech Biopharma Main Business
Table 135. Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 136. Acrotech Biopharma Latest Developments
Table 137. Takeda Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 138. Takeda Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 139. Takeda Main Business
Table 140. Takeda Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 141. Takeda Latest Developments
Table 142. Chiesi Farmaceutici Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 143. Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 144. Chiesi Farmaceutici Main Business
Table 145. Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 146. Chiesi Farmaceutici Latest Developments
Table 147. Gilead Sciences Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 148. Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 149. Gilead Sciences Main Business
Table 150. Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2019-2021E)
Table 151. Gilead Sciences Latest Developments
List of Figures
Figure 1. Liposomal and Lipid-based Nanoparticle Drug Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate 2016-2026 ($ Millions)
Figure 6. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Type in 2020
Figure 7. Liposomal and Lipid-based Nanoparticle Drug in Hospital
Figure 8. Global Liposomal and Lipid-based Nanoparticle Drug Market: Hospital (2016-2021) & ($ Millions)
Figure 9. Liposomal and Lipid-based Nanoparticle Drug in Retail Pharmacy
Figure 10. Global Liposomal and Lipid-based Nanoparticle Drug Market: Retail Pharmacy (2016-2021) & ($ Millions)
Figure 11. Liposomal and Lipid-based Nanoparticle Drug in Other
Figure 12. Global Liposomal and Lipid-based Nanoparticle Drug Market: Other (2016-2021) & ($ Millions)
Figure 13. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Application in 2020
Figure 14. Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Player in 2020
Figure 15. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Regions (2016-2021)
Figure 16. Americas Liposomal and Lipid-based Nanoparticle Drug Market Size 2016-2021 ($ Millions)
Figure 17. APAC Liposomal and Lipid-based Nanoparticle Drug Market Size 2016-2021 ($ Millions)
Figure 18. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size 2016-2021 ($ Millions)
Figure 19. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size 2016-2021 ($ Millions)
Figure 20. Americas Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Country in 2020
Figure 21. Americas Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Type in 2020
Figure 22. Americas Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Application in 2020
Figure 23. United States Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2016-2021 ($ Millions)
Figure 24. Canada Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2016-2021 ($ Millions)
Figure 25. Mexico Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2016-2021 ($ Millions)
Figure 26. APAC Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Regions in 2020
Figure 27. APAC Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Type in 2020
Figure 28. APAC Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Application in 2020
Figure 29. China Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2016-2021 ($ Millions)
Figure 30. Japan Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2016-2021 ($ Millions)
Figure 31. Korea Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2016-2021 ($ Millions)
Figure 32. Southeast Asia Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2016-2021 ($ Millions)
Figure 33. India Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2016-2021 ($ Millions)
Figure 34. Australia Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2016-2021 ($ Millions)
Figure 35. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Country in 2020
Figure 36. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Type in 2020
Figure 37. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Application in 2020
Figure 38. Germany Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2016-2021 ($ Millions)
Figure 39. France Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2016-2021 ($ Millions)
Figure 40. UK Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2016-2021 ($ Millions)
Figure 41. Italy Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2016-2021 ($ Millions)
Figure 42. Russia Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2016-2021 ($ Millions)
Figure 43. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Region in 2020
Figure 44. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Type in 2020
Figure 45. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Application in 2020
Figure 46. Egypt Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2016-2021 ($ Millions)
Figure 47. South Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2016-2021 ($ Millions)
Figure 48. Israel Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2016-2021 ($ Millions)
Figure 49. Turkey Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2016-2021 ($ Millions)
Figure 50. GCC Country Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2016-2021 ($ Millions)
Figure 51. Americas Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 52. APAC Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 53. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 54. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 55. United States Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 56. Canada Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 57. Mexico Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 58. Brazil Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 59. China Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 60. Japan Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 61. Korea Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 62. Southeast Asia Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 63. India Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 64. Australia Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 65. Germany Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 66. France Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 67. UK Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 68. Italy Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 69. Russia Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 70. Spain Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 71. Egypt Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 72. South Africa Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 73. Israel Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 74. Turkey Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)
Figure 75. GCC Country Liposomal and Lipid-based Nanoparticle Drug Market Size 2021-2026 ($ Millions)

※본 조사보고서 [세계의 리포좀 및 지질 나노 입자 약품 시장예측 2021년-2026년] (코드 : LPI-2201K00089) 판매에 관한 면책사항을 반드시 확인하세요.

※본 조사보고서 [세계의 리포좀 및 지질 나노 입자 약품 시장예측 2021년-2026년] 에 대해서 E메일 문의는 여기를 클릭하세요.

※당 사이트에 없는 조사자료도 취급 가능한 경우가 많으니 문의 주세요!

[이하, 관련 보고서 소개]

세계의 리포좀 및 지질 나노 입자 드럭 딜리버리 시스템 시장예측 2021년-2026년
LPI-2201K00088 / LP Information / 2021년 12월 / 본 조사보고서는 리포좀 및 지질 나노 입자 드럭 딜리버리 시스템의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아,...According to this latest study, the 2021 growth of Liposomal and Lipid Nanoparticle Drug Delivery Systems will have significant change from previous year. By the most conservative estimates of global Liposomal and Lipid Nanoparticle Drug Delivery Systems market size (most likely outcome) will be a year-over-year revenue growth rate of...

세계의 리포좀 및 지질 드럭 딜리버리 시스템 시장예측 2021년-2026년
LPI-2201K00087 / LP Information / 2021년 12월 / 본 조사보고서는 리포좀 및 지질 드럭 딜리버리 시스템의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽,...According to this latest study, the 2021 growth of Liposomal and Lipid Drug Delivery Systems will have significant change from previous year. By the most conservative estimates of global Liposomal and Lipid Drug Delivery Systems market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in...

세계의 나노 입자 약물 전달 시스템 시장예측 2021년-2026년
LPI-2201K02377 / LP Information / 2021년 12월 / 본 조사보고서는 나노 입자 약물 전달 시스템의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일,...According to this latest study, the 2021 growth of Nanoparticle Drug Delivery Systems will have significant change from previous year. By the most conservative estimates of global Nanoparticle Drug Delivery Systems market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 3999.1...

세계의 펩타이드 기반 약물 시장예측 2021년-2026년
LPI-2201K02139 / LP Information / 2021년 12월 / 본 조사보고서는 펩타이드 기반 약물의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국,...According to this latest study, the 2021 growth of Peptide-based Drug will have significant change from previous year. By the most conservative estimates of global Peptide-based Drug market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 31480 million in 2020. Over...

세계의 JAK 억제제 베이스 항암제 시장예측 2021년-2026년
LPI-2201K00078 / LP Information / 2021년 12월 / 본 조사보고서는 JAK 억제제 베이스 항암제의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스,...According to this latest study, the 2021 growth of JAK Inhibitor Based Cancer Drug will have significant change from previous year. By the most conservative estimates of global JAK Inhibitor Based Cancer Drug market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from...

세계의 백금 기반 암 치료제 시장예측 2021년-2026년
LPI-2201K02153 / LP Information / 2021년 12월 / 본 조사보고서는 백금 기반 암 치료제의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스,...According to this latest study, the 2021 growth of Platinum based Cancer Drug will have significant change from previous year. By the most conservative estimates of global Platinum based Cancer Drug market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 1451...